Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
AKTX | US
-0.20
-3.33%
Healthcare
Biotechnology
30/06/2024
24/04/2026
5.80
5.80
5.80
5.80
Akari Therapeutics Plc a clinical-stage biopharmaceutical company focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities including paroxysmal nocturnal hemoglobinuria Guillain-Barré syndrome hematopoietic stem cell transplant-associated thrombotic microangiopathy and bullous pemphigoid as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London the United Kingdom.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
97.8%1 month
14066.1%3 months
8249.5%6 months
5903.8%-
-
3.07
-0.27
0.20
-0.06
-
-
-18.08M
70.44M
70.44M
-
-
-
-
-1.28K
2.26
0.41
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
2.68
Range1M
6.34
Range3M
6.34
Rel. volume
0.01
Price X volume
8.88K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Cassava Sciences Inc | SAVA | Biotechnology | 1.615 | 77.48M | -2.71% | n/a | 0.00% |
| Equillium Inc | EQ | Biotechnology | 2.16 | 76.52M | -0.46% | n/a | 2.71% |
| Fortress Biotech Inc | FBIOP | Biotechnology | 14.25 | 76.49M | 6.26% | n/a | 494.61% |
| XBiotech Inc | XBIT | Biotechnology | 2.51 | 76.46M | -0.79% | n/a | 5.08% |
| CNS PHARMACEUTICALS INC | CNSP | Biotechnology | 2.35 | 75.54M | -4.86% | n/a | -2.87% |
| Pliant Therapeutics Inc. | PLRX | Biotechnology | 1.24 | 75.39M | -1.59% | n/a | 15.34% |
| VANI | VANI | Biotechnology | 1.35 | 74.60M | 3.05% | n/a | 84.10% |
| PMV Pharmaceuticals Inc | PMVP | Biotechnology | 1.44 | 74.19M | 0.70% | n/a | 6.06% |
| SciSparc Ltd. Ordinary Shares | SPRC | Biotechnology | 6.69 | 69.29M | 1.67% | n/a | 1.00% |
| BeyondSpring Inc | BYSI | Biotechnology | 1.705 | 68.71M | 2.71% | n/a | -14.90% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Saga Communications Inc | SGA | Broadcasting - Radio | 11.765 | 73.67M | 1.69% | 14.48 | 7.10% |
| ILAG | ILAG | Building Products & Equipment | 3.9 | 70.43M | 6.56% | n/a | 5.48% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 21.77 | 33.16M | -2.81% | n/a | 204.46% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.57 | 11.01M | -3.37% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5165 | 7.55M | -0.67% | 0.03 | 16.03% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.38 | 3.52M | 0.23% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.199 | 1.89M | 1.38% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.27 | 699.77K | -6.62% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0055 | 507.18K | -37.50% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.06 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.07 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 8,249.54 | 72.80 | Riskier |
| Debt to Equity | -0.27 | -1.23 | Expensive |
| Debt to Assets | 0.20 | 0.25 | Cheaper |
| Market Cap | 70.44M | 3.66B | Emerging |